OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Cancer is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Subscription & copyright page	307
FBXW10: a male-biased E3 ligase in liver cancer	184
Engineering growth factor ligands and receptors for therapeutic innovation	179
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	173
Revumenib: a new era in acute leukemia treatment	170
Spliced to kill: RNA mis-splicing derived cancer neoantigens	166
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	157
Tumor-resident microbes: the new kids on the microenvironment block	148
Advisory Board and Contents	143
Subscription & copyright page	134
Subscription and copyright page	131
Navigating life as an early career researcher	130
Onco-condensates: formation, multi-component organization, and biological functions	129
Radiotherapy and immunotherapy: open questions and future strategies	126
Leveraging circulating microbial DNA for early cancer detection	126
Accessing the vasculature in cancer: revising an old hallmark	121
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	115
Engine shutdown: migrastatic strategies and prevention of metastases	115
Subscription & copyright page	112
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	112
GOT2 consider the tumor microenvironment	107
IDH-Mutant Brain Tumors Hit the Achilles’ Heel of Macrophages with R-2-Hydroxyglutarate	101
Crosstalk of T cells within the ovarian cancer microenvironment	88
Pannexin biology and emerging linkages to cancer	88
Chromosomal instability and aneuploidy as causes of cancer drug resistance	85

Advisory Board and Contents	81
Benefits and opportunities of the transgenic Oncopig cancer model	80
Recent developments in myeloid immune modulation in cancer therapy	75
Tumor immunology CRISPR screening: present, past, and future	73
Chromatin as an old and new anticancer target	72
Regulation of metastatic organotropism	71
Oncogenic competence: balancing mutations, cellular state, and microenvironment	67
Gut microbiota – a double-edged sword in cancer immunotherapy	66
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	65
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	65
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	63
Diet, nutrient supply, and tumor immune responses	63
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	62
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	60
Cell death, therapeutics, and the immune response in cancer	60
Subscription & copyright page	59
Subscription & copyright page	59
Advisory Board and Contents	58
Advisory Board and Contents	56
Palmitate paves the way to lung metastasis	55
Genetic immune escape in cancer: timing and implications for treatment	55
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	55
Clinical and translational relevance of intratumor heterogeneity	54
Advisory Board and Contents	53
Scaling data toward pan-cancer foundation models	53
Subscription & copyright page	52
β-Galactosylceramidase in cancer: friend or foe?	51
Insights on ErbB glycosylation – contributions to precision oncology	50
Cancer catecholamine conundrum	49
Inflammation: the incubator of the tumor microenvironment	48
The emerging field of oncolytic virus-based cancer immunotherapy	48
Advisory Board and Contents	47
Advisory Board and Contents	46
Advisory Board and Contents	46
Advisory Board and Contents	45
Advisory Board and Contents	45
Subscription and copyright page	45
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	44
Subscription & copyright page	43
B7-H3: a robust target for immunotherapy in prostate cancer	42
Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity	42
Redefining precision cancer prevention to promote health equity	41
Advancing cancer precision surgery with the tumor coagulome	41
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	41
Molecular and clinical insights into early-onset endometrial cancer	41
RHOA takes the RHOad less traveled to cancer	40
Emerging mechanisms of telomerase reactivation in cancer	40
Updating cancer research with patient-focused networks	39
Stress granules and hormetic adaptation of cancer	38
Targeting the mitochondrial unfolded protein response in cancer: opportunities and challenges	38

Circulating cell-free DNA-based multi-cancer early detection	38
Modeling metastasis in mice: a closer look	38
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	38
Prospects for understanding and exploiting the consequences of hyperactivation lethality	38
Advisory Board and Contents	37
Subscription & copyright page	37
Advisory Board and Contents	37
Advisory Board and Contents	36
Neoantigen-directed therapeutics in the clinic: where are we?	35
Cross-dressing of dendritic cells strengthens antitumor immunity	35
A macrophage-neutrophil program drives mammary carcinogenesis	35
Dissecting liver tumor heterogeneity to improve health equity	35
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	35
Leveraging space innovations for cancer breakthroughs on Earth	35
Beyond safety: suicide systems in cell-based cancer therapies	34
Time-of-day dependency of adoptive cell therapies	34
Immune response and inflammation in cancer health disparities	34
Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises	33
A tipping point in cancer epidemiology: embracing a life course exposomic framework	33
Functional heterogeneity of fibroblasts in primary tumors and metastases	33
Targeting TIM-3 to halt lung precancer progression	33
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	33
Advisory Board and Contents	32
Subscription & copyright page	32
Dying to survive: harnessing inflammatory cell death for better immunotherapy	31
Advisory Board and Contents	31
Ferroptosis vulnerability in FLT3-mutant leukemia	31
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	30
Clonal evolution and hierarchy in myeloid malignancies	29
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us	28
Space in cancer biology: its role and implications	28
Epigenetic basis and targeting of cancer metastasis	28
Advisory Board and Contents	27
Engineered bacterial therapeutics for detecting and treating CRC	27
Subscription & copyright page	27
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	27
Cancer cell adaptability: turning ribonucleoprotein granules into targets	27
Addressing the genetic/nongenetic duality in cancer with systems biology	26
Next-generation immunotherapies for brain metastatic cancers	26
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	26
The development of therapy related myeloid neoplasms in childhood cancer survivors	25
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	25
Lifileucel: the first cellular therapy approved for solid tumours	25
Immunomodulation by endothelial cells: prospects for cancer therapy	25
Genitourinary cancer neoadjuvant therapies: current and future approaches	25
Overstretched and overlooked: solving challenges faced by early-career investigators after the pandemic	25
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	25
NETscape or NEThance: tailoring anti-cancer therapy	25
Next-generation cancer vaccines and emerging immunotherapy combinations	25
Subscription & copyright page	24
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	24
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	24
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	24
Embracing diversity: macrophage complexity in cancer	23
Deciphering the roles of ABCB5 in normal and cancer cells	23
The extracellular matrix in cancer: from understanding to targeting	23
Persisting cancer cells are different from bacterial persisters	23
Successfully targeting the cancer system with metronomics for medulloblastoma	23
How cancer cells make and respond to interferon-I	22
Future perspectives on engineered T cells for cancer	22
Tissue architecture in tumor initiation and progression	22
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	22
Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	21
Subscription & copyright page	21
TET2, tumor control, and CAR T cell hyperproliferation	20
Defining obesity in the context of cancer: thinking beyond body mass index	20
Enhancing dendritic cells by inhibiting BCL2	20
Targeting ferroptosis in pancreatic cancer: a double-edged sword	20
Acetylation: a new target for protein degradation in cancer	20
Extracellular vesicle lipids in cancer immunoevasion	20
Zebrafish as a New Model to Study the Crosstalk between Tumor and Host Metabolism	20